$154.6 Million

Imago BioSciences, Inc.

Initial Public Offering

Bookrunner, July 2021

Imago BioSciences, Inc.

Imago BioSciences is a clinical-stage biopharmaceutical company discovering and developing small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in the production of blood cells in the bone marrow. The Company’s lead product candidate, bomedemstat, is being developed for the treatment of myeloproliferative neoplasms, or MPNs, a family of related, chronic cancers of the bone marrow.